Table 4

P. vivax treatment outcomes on day 28 (uncorrected), grouped by treatment, year(s), month(s), and site

ParameterPailin, PailinVeal Veng, Pursat DP, 2010, Aug–OctRovieng, Preah Vihear CQ, 2009, Sep–DecVeun Sai, Ratanakiri
CQ, 2008/09, Jul–JanCQ, 2009/10, Sep–MarDP, 2010/11, Aug–FebCQ, 2009, Oct–DecDP, 2010, Sep–Oct
No. of patients63485360604660
Day 158 (92.1)36 (75.0)0 (0.0)8 (13.3)44 (73.3)38 (82.6)17 (28.3)
Day 213 (20.6)1 (2.1)0 (0.0)0 (0.0)9 (15)12 (26.1)0 (0.0)
Day 30 (0.0)0 (0.0)0 (0.0)0 (0.0)2 (3.3)2 (4.3)0 (0.0)
Dropout by day 283 (4.8)3 (4.2)2 (3.2)3 (5)0 (0.0)0 (0.0)0 (0.0)
LCF (%)2 (3.3)0 (0.0)0 (0.0)0 (0.0)5 (8.3)4 (8.7)0 (0.0)
LPF (%)1 (1.7)2 (4.4)0 (0.0)0 (0.0)2 (3.3)4 (8.7)0 (0.0)
ACPR (day 28) (%)57 (95.0)43 (95.6)51 (100)57 (100.0)53 (88.3)38 (82.6)60 (100)
Cumulative risk of treatment failure (%)5.1 (1.7–14.9)4.4 (1.1–16.6)0 (0–6.1)0 (0–6.1)11.7 (5.7–22.9)17.4 (9.1–31.8)0 (0–6.1)
  • a LCF, late clinical failure; LPF, late parasitological failure; ACPR, adequate clinical and parasitological response; CI, confidence interval.